, were reviewed for resistant organisms (methicillin-resistant Staphylococcus aureus [MRSA], vancomycin-resistant enterococci [VRE], and resistant gram-negative bacilli). In the second study, residents admitted to the AGS during a 2-month period (n=92 admissions) had surveillance cultures (nares, gastrostomy site, wounds, and urine) for resistant organisms performed within 72 hours of admission.
MRSA in Latin
Aires De Sousa and colleagues from the Universidade Nova de Lisboa, Oeiras, Portugal, studied 493 methicillinresistant Staphylococcus aureus (MRSA) isolates recovered from 1996 to 1998 from 22 hospitals in five countries of Latin America: Argentina, Brazil, Chile, Uruguay, and Mexico. The isolates were examined for antimicrobial susceptibility and clonal type so as to define the endemic clones in those hospitals. The hybridization of Clal restriction digests with the rnecA-and Tn554-specific DNA probes combined with pulsed-field gel electrophoresis of chromosomal Smal digests (aaI-mecA::CM-Tn554::PFGE clonal types) documented not only the predominance and persistence of the Brazilian clone (XI::B::B) in Brazil (97%) and Argentina (86%) but also its massive dissemination to Uruguay (100%). Moreover, a close relative of the Brazilian clone (XI::kappa::B) was highly represented in Chile (53%), together with a novel clone (47%) (II::E'::F) resistant to penicillin, oxacillin, ciprofloxacin, chloramphenicol, clindamycin, erythromycin, and gentamicin. A unique clonal type (I::NH::M) was detected in Mexico among pediatric isolates and was resistant to penicillin, oxacillin, and gentamicin only.
This study clearly documented the very large capacity for geographic expansion and the persistence of the Brazilian clone, contributing not only to the increasing uniformity of the MRSA in South America but worldwide as well. 
Povidone-Iodine Versus Chlorhexidine Gluconate-Impregnated Dressing for Prevention of CVC Infections in Neonates
Neonates who require a central venous catheter (CVC) for prolonged vascular access experience high rates of catheter-related (CR) bloodstream infection (BSI). Garland and coinvestigators conducted a multicenter, randomized clinical trial to ascertain the efficacy of a novel chlorhexidine-impregnated dressing (Biopatch Antimicrobial Dressing; Johnson & Johnson Medical, Arlington, TX) on the CVC sites of neonates for the prevention of catheter-tip colonization, CR BSI, and BSI without a source. The trial was conducted in six level III neonatal intensive care units. Patients studied were neonates admitted to study units who would require a CVC for at least 48 hours. Eligible infants were randomized before catheter placement to 1 of the 2 catheter-site antisepsis regimens: (1) 10% povidone-iodine (PI) skin scrub, or (2) a 70% alcohol scrub followed by placement of a chlorhexidineimpregnated disk over the catheter insertion site. A transparent polyurethane dressing (Bioclusive Transparent
